The materials and information on the MS Center website are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a…
Read More
The diagnosis of “secondary progressive MS” has long been thought to mark a shift in the course of the disease from a primarily inflammatory process to a neurodegenerative one. Although the majority of people with…
Cladribine is an FDA approved chemotherapy treatment most often used to treat leukemia and lymphoma. By mid-2009, however, the therapy will likely head to the FDA and European EMEA for…
Fingolimod is an oral agent that is now being researched in three Phase III trials. This is the first of a new class of potential MS medications known as “S1P…
Laquinimod Laquinimod is an investigational, oral, once-daily therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). The therapy (licensed to Teva Neuroscience) received Fast Track designation—meaning the therapy demonstrated the…
To view the video presentations, scroll down and click on the images below. The presentation’s title and presenter name will appear once you click on the image you want to…
